Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Tamm

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Cancer|May 19, 2012
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicatorsMatthew H G Katz, Jason B Fleming, Priya Bhosale, et al.
Annals of Surgical Oncology|October 17, 2018
First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaPat Gulhati, Laura Prakash, Matthew H G Katz, et al.
Annals of Surgical Oncology|August 17, 2019
Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II TrialAlice C Wei, Fang-Shu Ou, Qian Shi, et al.
Gastroenterology|January 17, 2012
Frequent detection of pancreatic lesions in asymptomatic high-risk individualsMarcia Irene Canto, Ralph H Hruban, Elliot K Fishman, et al.
International Journal of Radiation Oncology, Biology, Physics|July 21, 2022
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker ValidationEugene J Koay, Mohamed Zaid, Maureen Aliru, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Cancer|May 19, 2012
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicatorsMatthew H G Katz, Jason B Fleming, Priya Bhosale, et al.
Annals of Surgical Oncology|October 17, 2018
First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaPat Gulhati, Laura Prakash, Matthew H G Katz, et al.
Annals of Surgical Oncology|August 17, 2019
Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II TrialAlice C Wei, Fang-Shu Ou, Qian Shi, et al.
Gastroenterology|January 17, 2012
Frequent detection of pancreatic lesions in asymptomatic high-risk individualsMarcia Irene Canto, Ralph H Hruban, Elliot K Fishman, et al.
International Journal of Radiation Oncology, Biology, Physics|July 21, 2022
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker ValidationEugene J Koay, Mohamed Zaid, Maureen Aliru, et al.
Pageof 2